Axonics Receives TGA Approval for R20 SNM Device Amidst Share Price Decline
Axonics Receives TGA Approval for R20 SNM Device Amidst Share Price Decline
Axonics, Inc. AXNX has garnered regulatory approval from the Therapeutic Goods Administration in Australia, allowing the company to introduce its innovative R20 rechargeable sacral neuromodulation (SNM) system to the market. The cutting-edge R20 device boasts a 20-year functional lifespan, reducing recharging frequency to just once every 6 to 10 months for a mere hour. With ...












